2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents.

摘要

Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R<1 >are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.